BioMarin has announced disappointing results from the Phase I clinical trial of 'BMN-195' and it has halted development of the compound. BMN-195 is an oral drug with the potential to increase the amount of the protein utrophin in the muscles. Utrophin is thought to be able to substitute for the missing dystrophin protein in boys with Duchenne muscular dystrophy. The Phase 1 clinical trial administered BMN-195 to a small number of healthy volunteers...
More...
More...